Biotech firm Bio-Techne missed its first-quarter revenue estimates on Wednesday, hurt by sluggish demand for its products amid soft biotech funding environment in China.

Nuvation Bio's launch for lung cancer shows strong promise. Read more on what investors should know about this biotech.

KANSAS CITY, Kan.--(BUSINESS WIRE)--KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a leading ...

Selected by a Distinguished Jury of Global Biopharma Leaders for Dren Bio’s Outstanding Innovation, Impact, and Scientific Excellence – SAN CARLOS, ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Wednesday reported a loss of $48.2 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of ...

A Renton-based cleantech startup that converts plant-based oils into low-carbon and recyclable bio-epoxy resins is among 20 ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic ...

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that it will have an oral and a poster presentation at the ...

WELLESLEY HILLS, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...

Bio-Techne (($TECH)) has held its Q1 earnings call. Read on for the main highlights of the call. Bio-Techne’s earnings call presented a mixed ...